Biotech News

ARS Pharma to Report Third Quarter 2026 Financial Results

ARS Pharmaceuticals (SPRY)ARS PharmaceuticalsEarnings

ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions, today announced the company will host a conference call and webcast on Thursday, November 5, 2026, at 1:30 p.m. PT / 4:30 p.m. ET to review its third quarter 2026 financial results.

Related news

ARS Pharmaceuticals

Needle-Free Epinephrine Company ARS Pharmaceuticals commercializes neffy, an epinephrine nasal spray for Type I allergic reactions, including anaphylaxis. Neffy is an approved needle-free emergency epinephrine treatment in the United States and European Union. Neffy Commercialization The company is building U.S. sales, payer access,...

Recent company news

Stock data

Close
3.36 USD
Market cap
883.8M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States